VOLITIONRX LTD
No SEC Form 4 filings for $VNRX in the last 30 days.
See all $VNRX insider activity →VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management X
VolitionRx (VNRX) validated its Nu.Q NETs biomarker for sepsis, predicting mortality and kidney therapy needs. Published in Critical Care Medicine, the study found higher levels in septic shock, aiding risk stratification. The $0.34 stock fell 10.37%, amid a $2.8B market opportunity. The company completed a 1-for-20 reverse stock split on April 28, 2026.
VolitionRx reported 112% H1 revenue growth to $1.4M. The company highlighted progress in sepsis testing, lung cancer reimbursement, and cancer detection. It also announced a collaboration with Sysmex Corporation and active licensing discussions with global diagnostic leaders. Volition aims for a $5M milestone in veterinary diagnostics and a reimbursement submission in France by year-end.
Over the past 7 days, alphai's AI scored 2 news stories mentioning VNRX (VOLITIONRX LTD). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent VNRX coverage spans corporate actions, earnings and technology.
The company converted convertible notes into common stock, diluting existing shareholders.
Positive trial data may boost valuation and attract partnership interest.
Potential modest upside as the company shows commercial momentum, but scale is limited.
Dilution of existing shareholders and modest cash inflow from note conversions.
This is a results-and-update filing, but the scraped text does not include the actual financial figures or guidance, limiting immediate trading signals.
alphai scores every news story that mentions VNRX with an AI model for sentiment and relevance, and aggregates insider trades from VOLITIONRX LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management X
1 min readVolitionRx (VNRX) validated its Nu.Q NETs biomarker for sepsis, predicting mortality and kidney therapy needs. Published in Critical Care Medicine, the study found higher levels in septic shock, aiding risk stratification. The $0.34 stock fell 10.37%, amid a $2.8B market opportunity. The company completed a 1-for-20 reverse stock split on April 28, 2026.
2 min readVolitionRx reported 112% H1 revenue growth to $1.4M. The company highlighted progress in sepsis testing, lung cancer reimbursement, and cancer detection. It also announced a collaboration with Sysmex Corporation and active licensing discussions with global diagnostic leaders. Volition aims for a $5M milestone in veterinary diagnostics and a reimbursement submission in France by year-end.
2 min readVOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management X
1 min readVOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 13, 2026 /PRNewswire/ -- Volit
3 min readVolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of about $0.4 million, flat versus Q2 2025, and first-half 2026 revenue of $1.4 million, up 112% year over year. Operating expenses fell 32% and operating loss was $4.2 million. The company said it is discussing licensing deals, including a Sysmex collaboration, and expects a $5 million milestone from a Nu.Q Vet feline assay peer review.
4 min readVolitionRx Limited (NYSE American: VNRX) scheduled a conference call for Aug. 14, 2026 at 8:30 a.m. ET to discuss its Q2 2026 financial and operating results and provide a business update. The call will be hosted by company executives and include a live webcast and a replay until Aug. 28, 2026.
1 min readVOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management X
2 min readVOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. vnrx_8k.htm 0000093314 false --12-31 0000093314 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O
2 min readVolitionRx Limited (NYSE American: VNRX) said a real-world study with Hospices Civils de Lyon found its Nu.Q® Cancer assay (H3K27Me3-nucleosomes) in newly diagnosed lung cancer patients was associated with cancer stage and poorer outcomes. Volition reported an OS analysis using a cut-off and a Cox model stratifying low/high mortality risk, and said HCL clinical certification is complete and a France reimbursement dossier is planned.
5 min read
